Acrivon Therapeutics, Inc. (ACRV) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary Generative Phosphoproteomics platform (AP3). The company has no approved products and has not generated revenue from drug sales. Its primary focus is advancing its lead candidate, ACR-368 (prexasertib), in a registrational Phase 2 trial for endometrial cancer, and its second clinical asset, ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19,680) | $(16,486) |
| Net Loss Per Share (Basic & Diluted) | $(0.51) | $(0.73) |
| Operating Expenses | $21,662 | $17,668 |
| Research & Development (R&D) | $15,414 | $11,473 |
| General & Administrative (G&A) | $6,248 | $6,195 |
| Cash, Cash Equivalents & Investments | $164,835 | $165,291 |
| Accumulated Deficit | $(216,656) | $(132,906) |
| Net Cash Used in Operating Activities | $(19,535) | $(17,083) |
Note: Cash, cash equivalents, and investments are derived from the Balance Sheet (Cash $39,154 + Short-term investments $110,481 + Long-term investments $15,195 + Restricted cash $198 = $164,835).
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $3.2 million (19.4%) year-over-year, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose by $3.9 million. This was due to a $1.5 million increase in costs for the ACR-368 clinical trial and $1.2 million in new costs for the ACR-2316 program following its IND clearance and Phase 1 initiation in late 2024.
- Improved Interest Income: Total other income increased by $0.8 million, primarily due to higher interest income ($2.0 million vs. $1.4 million) earned on cash and investments.
- Investment Portfolio: The company actively managed its investment portfolio, with $39.5 million in proceeds from maturities offset by $20.2 million in new purchases during the quarter.
Guidance, Outlook, and Risks
- Clinical Progress:
- ACR-368: Reported positive interim data in endometrial cancer. Among 20 biomarker-positive (BM+) patients, the confirmed Overall Response Rate (ORR) was 35% and Disease Control Rate (DCR) was 80%. The FDA has granted Breakthrough Device designation for the companion diagnostic assay.
- ACR-2316: Phase 1 trial is ongoing. Dose levels 1 and 2 were cleared without safety concerns. Initial clinical activity was observed at Dose Level 3, showing significant reduction in metastatic lesions.
- Liquidity and Runway: As of March 31, 2025, the company held $164.8 million in cash and investments. Management projects this capital is sufficient to fund operations into the second quarter of 2027.
- Subsequent Events: In April 2025, the company incurred $1.2 million in development milestone payments to Akoya Biosciences under their companion diagnostic agreement.
- Risks: The company expects to continue incurring significant losses. Future funding requirements depend on clinical trial outcomes, regulatory approvals, and the ability to raise additional capital. Failure to secure funding could force delays in development.
Key Facts for Investor Verification
- Capital Runway: Verify the sustainability of the projected runway into Q2 2027 given the increasing burn rate (approx. $19.5M cash used in operations for Q1).
- ACR-368 Data Validation: Confirm the durability of the 35% ORR in the endometrial cancer trial and the timeline for full data readout and potential regulatory submission.
- ACR-2316 Safety Profile: Monitor upcoming safety data from higher dose levels in the Phase 1 trial to ensure no dose-limiting toxicities emerge.
- Milestone Obligations: Track future milestone payments to partners (Lilly and Akoya), which could total up to $168 million and $20.3 million respectively upon achievement of specific development and commercial goals.
- Dilution Risk: Note the existence of 7.06 million pre-funded warrants and 6.5 million stock options outstanding, which represent potential dilution upon exercise.